Biomanufacturing framework could boost microbial production efficiency
Research findings support the design of robust microbial processes for pharmaceutical products.
List view / Grid view
Research findings support the design of robust microbial processes for pharmaceutical products.
Novel approach holds potential to reduce the industry’s dependence on coconut and palm oil extraction for bioproduction of short- and medium-chain fatty acids.
The impurities research illustrates an approach that could offer a simpler and more flexible downstream purification process.
The new biopharmaceutical production facility represents the CDMO’s largest single investment at its headquarters in Lauphei, Germany.
This update includes sterile manufacturing, bio-manufacturing, cell line development and radiopharmaceuticals.
EPR Issue 2 includes articles on the impact of tariffs on the pharmaceutical supply chain, advances in bioprocessing, manufacturing and more.
This article explores how artificial intelligence (AI) is forming an essential pillar of staying competitive in pharmaceutical manufacturing, with its adoption ensuring greater efficiency of medicine production in this fast-evolving sector.
Here, Shidong Shi, Head of Upstream Process Development, and Li Yang, Vice President of CMC Development at Altruist Biologics, discuss the key trends in upstream processing and highlight their approach for overcoming challenges in the field.
European Pharmaceutical Review Issue 5 includes articles on bioprocessing, biologics, sustainability, and drug formulation.
This bioproduction investment in Lyon, France supports Sanofi in its goals to lead in the immunology sector.
Advancement in technology like automation is boosting the adoption of single-use technology rocking bioreactors in the bioprocess market, research says.
European Pharmaceutical Review Issue 4 includes articles on regulation, bioproduction, environmental monitoring, packaging and drug delivery.
The automated system “significantly improved process control”, resulting in greater productivity of a small-molecule drug substance.
The method has potential in both biomanufacturing and production of autologous cell therapies, the research suggests.
The paper presents an “efficient and scalable GMP-compliant process” for purifying a fusogenic oncolytic virus (rVSV-NDV).